Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
LRMR · against 324 other Healthcare companies of similar size
Ranked #208 of 325 · scores higher than 11% of peers
Bars: peers in each 10-point band of the valuation score118 peers with a valuation score of 0–9, including LRMR · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | LRMR | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 310 reported | -80.7% | -0.3% | 5% | 30% | |
| EBITDA yieldHigher is better · 331 reported | -156.5% | 2.0% | 5% | 50% | |
| Free cash flow yieldHigher is better · 168 reported | -59.2% | -9.3% | 8% | 20% | |
| Book yieldHigher is better · 315 reported | 48.0% | 52.2% | 46% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 208 | 327M USD | 8 | 11 | |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 208 |
| 172M USD |
| 8 |
| 41 |
| 208 | 319M USD | 8 | 28 |
| 208 | 255M USD | 8 | 36 |
| 208 | 264M USD | 8 | 30 |
| 208 | 255M USD | 8 | 38 |
| 208 | 264M USD | 8 | 24 |
| 208 | 441M USD | 8 | 34 |
| 208 | 366M CHF (≈$421M) | 8 | 23 |